Clinical efficacy and safety of moxibustion as adjuvant therapy for COPD in stable phase: a Meta-analysis.
10.13703/j.0255-2930.20200213-k0004
- Author:
Jia-Li LOU
1
;
Hai-Ju SUN
1
;
Xiao-Yu LI
1
;
Han-Tong HU
1
;
Ya-Jun ZHANG
1
;
Yong-Liang JIANG
2
;
Jian-Qiao FANG
2
Author Information
1. Third Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, China.
2. Acupuncture Neurobiology Laboratory, Third Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Key Laboratory of Acupuncture Neurology, Hangzhou 310053.
- Publication Type:Meta-Analysis
- Keywords:
Meta-analysis;
chronic obstructive pulmonary disease (COPD);
moxibustion therapy;
randomized controlled trial (RCT)
- MeSH:
Humans;
Lung;
Moxibustion;
Pulmonary Disease, Chronic Obstructive/therapy*;
Treatment Outcome
- From:
Chinese Acupuncture & Moxibustion
2021;41(4):451-457
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically evaluate the efficacy and safety of conventional therapy combined with moxibustion in the treatment of chronic obstructive pulmonary disease (COPD) in stable phase based on Meta-analysis medicine.
METHODS:The randomized controlled trials (RCTs) of moxibustion as adjuvant therapy for COPD were retrieved from the databases of CNKI, Wanfang, SinoMed, PubMed, Web of Science, Cochrane Library and Ebsco. RevMan5.3 software was used for Meta analysis, and the quality of evidence was evaluated according to GRADE standards.
RESULTS:A total of 16 RCTs were included, involving 1425 patients. The results of Meta-analysis showed that: compared with the conventional treatment, ①the adjuvant therapy with moxibustion had advantages in reducing the number of acute exacerbations [
CONCLUSION:The efficacy of moxibustion as adjuvant therapy for COPD in stable phase is better than that of simple conventional therapy. Due to insufficient clinical evidence and the limitations of this study, clinical safety is unclear and further evidence is needed to support the results.
